Open Access. Powered by Scholars. Published by Universities.®
Zucker School of Medicine at Hofstra/Northwell
BTK;; Chronic lymphocytic leukemia;; Comorbidities;; Elderly;; PI3K;; brutons tyrosine kinase;; phosphoinositide 3-kinase;; dose fludarabine;; btk inhibitors;; older patients;; open-label;; in-vivo;; survival;; comorbidity;; rituximab;; Oncology;; Hematology
Articles 1 - 1 of 1
Full-Text Articles in Hematology
Therapeutic Potential Of New B Cell-Targeted Agents In The Treatment Of Elderly And Unfit Patients With Chronic Lymphocytic Leukemia, K. R. Rai
Journal Articles
Chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, is primarily a disease of the elderly, with most patients >= 65 years of age and having at least one major comorbidity. Aggressive chemoimmunotherapy regimens recommended to achieve remission and improve survival in young, fit patients are often poorly tolerated in elderly and/or less physiologically fit ("unfit") patients, necessitating alternative treatment options. Although patient age, fitness, and comorbidities are key considerations in the selection of a treatment regimen, historically, clinical trials have been limited to young, fit patients by virtue of the ethical concerns associated with potential …